Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ2YBE)

Drug Name
Lexipafant Drug Info
Synonyms
LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
Indication
Disease Entry ICD 11 Status REF
Nerve injury ND56.4 Phase 2 [1]
Hepatovirus infection 1E51 Investigative [2]
Cross-matching ID
PubChem CID
9804204
CAS Number
CAS 139133-26-9
TTD Drug ID
DMZ2YBE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [4]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [5]
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [6]
Tenofovir DM1IS6U Chronic hepatitis B virus infection Approved [4]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [7]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [8]
Delavirdine DM3NF5G Human immunodeficiency virus infection 1C62 Approved [7]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [7]
Rilpivirine DMJ0QOW Human immunodeficiency virus infection 1C62 Approved [2]
Etravirine DMGV8QU Human immunodeficiency virus-1 infection 1C62 Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-activating factor receptor (PTAFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [7]
RUPATADINE DMBPN7T N. A. N. A. Phase 4 [10]
ISRAPAFANT DMP61YB Asthma CA23 Phase 3 [11]
CMI-392 DM1NCUY Psoriasis vulgaris EA90 Phase 2 [12]
YM-264 DMAZNVX Sepsis 1G40-1G41 Phase 2 [13]
Dersalazine DMH96JW Inflammatory bowel disease DD72 Phase 2 [14]
60P002 DMHBN8X Dengue 1D20-1D2Z Phase 2 [15]
PegCNTF DMW7VGZ Obesity 5B81 Phase 1 [16]
FOROPAFANT DML1DGP Asthma CA23 Discontinued in Phase 3 [17]
BN 50730 DMZK70E Asthma CA23 Discontinued in Phase 3 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [2]
Platelet-activating factor receptor (PTAFR) TTQL5VC PTAFR_HUMAN Modulator [3]

References

1 Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20.
2 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
3 Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
4 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
5 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
6 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
9 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
10 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
11 Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
12 Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
13 Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
14 The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
15 Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
16 Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21.
17 Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51.
18 Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11.